The European Heart Journal has published the abstract of a new study that concludes that endothelial glycocalyx thickness is reduced in patients with psoriasis and is associated with impaired coronary and myocardial function, and vascular atherosclerosis.
The study used GlycoCheck™ endothelial glycocalyx testing technology to measure glycocalyx barrier properties in psoriasis, as well as their correlation with coronary microcirculatory function and markers of myocardial deformation and atherosclerosis (carotid intima-media thickness, cIMT).
The study, titled “Endothelial glycocalyx integrity and microvascular perfusion are associated with novel echocardiographic markers and carotid intima-media thickness in patients with psoriasis” was conducted by researchers from National & Kapodistrian University of Athens and Attikon University Hospital in Athens, Greece. The full study is expected to be released in coming weeks.
With this new peer-reviewed and published paper, there are now 80 studies globally that have used GlycoCheck.
Dr. Hans Vink, the inventor and co-founder of GlycoCheck and one of the world’s leading researchers of endothelial glycocalyx health, said “This paper confirms that for patients who have a damaged glycocalyx there is reduced capillary density. Increase in glycocalyx damage is associated with reduced coronary flow reserve. The loss of capillary density is related to worsened properties of the left ventricle and increased intima-media thickness, concluding that an increase in glycocalyx damage can be correlated with impaired heart function.”
“This paper sheds a new light on psoriasis as an outward expression of what’s happening at the cardiovascular level,” said Robert M. Long, co-founder of GlycoCheck and CEO of Microvascular Health Solutions.
Mr. Long adds that “skin problems such as psoriasis are an early warning sign of glycocalyx damage and the loss of microcirculation.”
Both Dr. Vink and Mr. Long are the co-creators of Endocalyx Pro™ which has been used by people with skin problems like psoriasis. “We’ve had multiple people tell us that after using Endocalyx Pro their psoriasis seemed to disappear,” said Mr. Long. He added “these links warrant further study and validation.”
Endocalyx Pro restores and maintains the endothelial glycocalyx lining inside the capillaries and improves capillary density and function.* Healthy skin, hair and eyes depend on a steady supply of oxygen and nutrients in order to renew, grow, and stay healthy.* As it rejuvenates the glycocalyx, this supply line is improved.*
Endocalyx Pro helps the glycocalyx optimize capillary structure, while actually increasing functional capillary density.* This means more blood cells reach more muscle, skin, and nerve cells, restoring warmth, feeling and comfort.*
Endocalyx Pro is quickly gaining recognition as the tested product clinically shown to restore, regenerate, and protect the endothelial glycocalyx. The number of healthcare practitioners who now recommend Endocalyx Pro in their clinics is quickly growing.
GlycoCheck has been used in more than 140 academic hospitals and universities worldwide and in early 2022 will be available for individual healthcare practitioner office use. To be placed on the waiting list for the practitioner version, please go to GlycoCheck.com and complete the information request form.
Healthcare practitioners who are interested in offering Endocalyx Pro to their patients can complete the contact form at Microvascular.com to receive information about pricing and delivery.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
